Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
Bullboard Posts
User Avatar Image
(1507)
•••
Post by wildbird1on Feb 27, 2019 12:11pm
148 Views
Post# 29418141

900,000 Healthcare providers...

900,000 Healthcare providers...I love reading PressRelease....


EXAS:US($92.00US) PressRelease Fev 27,2019...EXACT said (QUOTE) '' Since 2014 more than 150,000 healthcare providers have ordered Cologuard(End of Quote)''.


Genenews PressRelease Dec 28, 2018...Genenews said (QUOTE) '' Genenews has entered into an agreements with MultiPlan Inc. MultiPlan Inc contracts with more than 900,000 healthcare providers across the US(End of Quote)''.

Will be very interesting to see how many of these 900,000 healthcare providers will order one (or more) of Genenews 4 blood cancer tests(ColonSentry, EarlyCDT-Lung,Prostate Health Index and BreastSentry).

Remember Exact:US($92.00US) has only one Poop test at hand(Cologuard), and is working very hard to come up with a blood test, that could be available only in a few years.



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities